Browse IL13

Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted.
Domain PF03487 Interleukin-13
Function

Cytokine (PubMed:8096327, PubMed:8097324). Inhibits inflammatory cytokine production (PubMed:8096327). Synergizes with IL2 in regulating interferon-gamma synthesis (PubMed:8096327). May be critical in regulating inflammatory and immune responses (PubMed:8096327, PubMed:8097324). Positively regulates IL31RA expression in macrophages (By similarity).

> Gene Ontology
 
Biological Process GO:0001774 microglial cell activation
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001906 cell killing
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002067 glandular epithelial cell differentiation
GO:0002237 response to molecule of bacterial origin
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002279 mast cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002377 immunoglobulin production
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002448 mast cell mediated immunity
GO:0002637 regulation of immunoglobulin production
GO:0002639 positive regulation of immunoglobulin production
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002886 regulation of myeloid leukocyte mediated immunity
GO:0002888 positive regulation of myeloid leukocyte mediated immunity
GO:0006816 calcium ion transport
GO:0006818 hydrogen transport
GO:0006874 cellular calcium ion homeostasis
GO:0006875 cellular metal ion homeostasis
GO:0006887 exocytosis
GO:0007204 positive regulation of cytosolic calcium ion concentration
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0009306 protein secretion
GO:0009612 response to mechanical stimulus
GO:0010155 regulation of proton transport
GO:0010522 regulation of calcium ion transport into cytosol
GO:0010524 positive regulation of calcium ion transport into cytosol
GO:0010959 regulation of metal ion transport
GO:0015672 monovalent inorganic cation transport
GO:0015992 proton transport
GO:0017157 regulation of exocytosis
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0030323 respiratory tube development
GO:0030324 lung development
GO:0030856 regulation of epithelial cell differentiation
GO:0030857 negative regulation of epithelial cell differentiation
GO:0030858 positive regulation of epithelial cell differentiation
GO:0030888 regulation of B cell proliferation
GO:0030890 positive regulation of B cell proliferation
GO:0031341 regulation of cell killing
GO:0031342 negative regulation of cell killing
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032418 lysosome localization
GO:0032496 response to lipopolysaccharide
GO:0032601 connective tissue growth factor production
GO:0032643 regulation of connective tissue growth factor production
GO:0032723 positive regulation of connective tissue growth factor production
GO:0032844 regulation of homeostatic process
GO:0032845 negative regulation of homeostatic process
GO:0032846 positive regulation of homeostatic process
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033002 muscle cell proliferation
GO:0033003 regulation of mast cell activation
GO:0033005 positive regulation of mast cell activation
GO:0033006 regulation of mast cell activation involved in immune response
GO:0033008 positive regulation of mast cell activation involved in immune response
GO:0033860 regulation of NAD(P)H oxidase activity
GO:0033861 negative regulation of NAD(P)H oxidase activity
GO:0034762 regulation of transmembrane transport
GO:0034764 positive regulation of transmembrane transport
GO:0034765 regulation of ion transmembrane transport
GO:0034767 positive regulation of ion transmembrane transport
GO:0035094 response to nicotine
GO:0042100 B cell proliferation
GO:0042113 B cell activation
GO:0042116 macrophage activation
GO:0042505 tyrosine phosphorylation of Stat6 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042525 regulation of tyrosine phosphorylation of Stat6 protein
GO:0042526 positive regulation of tyrosine phosphorylation of Stat6 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0043030 regulation of macrophage activation
GO:0043032 positive regulation of macrophage activation
GO:0043270 positive regulation of ion transport
GO:0043279 response to alkaloid
GO:0043299 leukocyte degranulation
GO:0043300 regulation of leukocyte degranulation
GO:0043302 positive regulation of leukocyte degranulation
GO:0043303 mast cell degranulation
GO:0043304 regulation of mast cell degranulation
GO:0043306 positive regulation of mast cell degranulation
GO:0045055 regulated exocytosis
GO:0045471 response to ethanol
GO:0045576 mast cell activation
GO:0045921 positive regulation of exocytosis
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0046651 lymphocyte proliferation
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048146 positive regulation of fibroblast proliferation
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050708 regulation of protein secretion
GO:0050714 positive regulation of protein secretion
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050871 positive regulation of B cell activation
GO:0051047 positive regulation of secretion
GO:0051208 sequestering of calcium ion
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051222 positive regulation of protein transport
GO:0051235 maintenance of location
GO:0051238 sequestering of metal ion
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051279 regulation of release of sequestered calcium ion into cytosol
GO:0051281 positive regulation of release of sequestered calcium ion into cytosol
GO:0051282 regulation of sequestering of calcium ion
GO:0051283 negative regulation of sequestering of calcium ion
GO:0051341 regulation of oxidoreductase activity
GO:0051354 negative regulation of oxidoreductase activity
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0055074 calcium ion homeostasis
GO:0060401 cytosolic calcium ion transport
GO:0060402 calcium ion transport into cytosol
GO:0060428 lung epithelium development
GO:0060433 bronchus development
GO:0060479 lung cell differentiation
GO:0060480 lung goblet cell differentiation
GO:0060481 lobar bronchus epithelium development
GO:0060482 lobar bronchus development
GO:0060487 lung epithelial cell differentiation
GO:0060541 respiratory system development
GO:0060627 regulation of vesicle-mediated transport
GO:0061140 lung secretory cell differentiation
GO:0061141 lung ciliated cell differentiation
GO:0070509 calcium ion import
GO:0070588 calcium ion transmembrane transport
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0070838 divalent metal ion transport
GO:0070997 neuron death
GO:0071214 cellular response to abiotic stimulus
GO:0071260 cellular response to mechanical stimulus
GO:0071496 cellular response to external stimulus
GO:0071604 transforming growth factor beta production
GO:0071634 regulation of transforming growth factor beta production
GO:0071635 negative regulation of transforming growth factor beta production
GO:0072343 pancreatic stellate cell proliferation
GO:0072503 cellular divalent inorganic cation homeostasis
GO:0072507 divalent inorganic cation homeostasis
GO:0072511 divalent inorganic cation transport
GO:0072577 endothelial cell apoptotic process
GO:0090279 regulation of calcium ion import
GO:0090280 positive regulation of calcium ion import
GO:0097278 complement-dependent cytotoxicity
GO:0097305 response to alcohol
GO:0097553 calcium ion transmembrane import into cytosol
GO:0097696 STAT cascade
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901246 regulation of lung ciliated cell differentiation
GO:1901247 negative regulation of lung ciliated cell differentiation
GO:1901249 regulation of lung goblet cell differentiation
GO:1901251 positive regulation of lung goblet cell differentiation
GO:1902656 calcium ion import into cytosol
GO:1903169 regulation of calcium ion transmembrane transport
GO:1903305 regulation of regulated secretory pathway
GO:1903307 positive regulation of regulated secretory pathway
GO:1903532 positive regulation of secretion by cell
GO:1903659 regulation of complement-dependent cytotoxicity
GO:1903660 negative regulation of complement-dependent cytotoxicity
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:1904062 regulation of cation transmembrane transport
GO:1904064 positive regulation of cation transmembrane transport
GO:1904427 positive regulation of calcium ion transmembrane transport
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:1904951 positive regulation of establishment of protein localization
GO:2000021 regulation of ion homeostasis
GO:2000229 regulation of pancreatic stellate cell proliferation
GO:2000231 positive regulation of pancreatic stellate cell proliferation
GO:2000351 regulation of endothelial cell apoptotic process
GO:2000352 negative regulation of endothelial cell apoptotic process
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005144 interleukin-13 receptor binding
Cellular Component GO:0009897 external side of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04630 Jak-STAT signaling pathway
hsa04664 Fc epsilon RI signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-6783783: Interleukin-10 signaling
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL13 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL13 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26081225Esophageal AdenocarcinomaInhibit immunity (T cell function)Because the progression from squamous esophagitis to Barrett's esophagus is accompanied by a transition from a TH1 to TH2 immune response, we hypothesized that the TH2 cytokines IL4/IL13 could contribute to PD-L2 induction. We confirmed that these cytokines can augment PD-L2 expression in esophageal adenocarcinoma cell lines.
19494278Colon Carcinoma; Prostate CarcinomaInhibit immunityPGDH-mediated antitumor effect was associated with attenuated tumor-induced immune suppression and substantially reduced secretion of immunosuppressive mediators and cytokines such as PGE(2), IL-10, IL-13, and IL-6 by intratumoral CD11b cells. We show also that introduction of 15-PGDH gene in tumor tissue is sufficient to redirect the differentiation of intratumoral CD11b cells from immunosuppressive M2-oriented F4/80(+) tumor-associated macrophages (TAM) into M1-oriented CD11c(+) MHC class II-positive myeloid APCs.
24892809biliary atresiaInhibit immunityThe IL-33-dependent proliferative response was mediated by an increase in the number of type 2 innate lymphoid cells (ILC2s), which released high levels of IL-13 that in turn promoted cholangiocyte hyperplasia.
24030977GliomaInhibit immunity (T cell function)Mice genetically deficient for IL-4Rα exhibited a slower growth of glioma associated with reduced production in the glioma microenvironment of arginase, a marker of myeloid suppressor cells, which is critical for their T-cell inhibitory function. Supporting this result, investigations using bone marrow-derived myeloid cells showed that IL-4Rα mediates IL-13-induced production of arginase.
18490770GlioblastomaInhibit immunityIn addition, direct ex vivo analysis of cytokine expression by TIL from GBM demonstrated significant numbers of IL-4/IL-13 positive cells, cytokines that are integral in the cell-mediated repression of tumor immunity in experimental models.
17016559colon carcinomaInhibit immunityCD11b+IL-4Ralpha+ cells produced IL-13 and IFN-gamma and integrated the downstream signals of these cytokines to trigger the molecular pathways suppressing antigen-activated CD8+ T lymphocytes. Analogous immunosuppressive circuits were active in CD11b+ cells present within the tumor microenvironment.
16899618ContralateralPromote immunityCell depletion experiments in tumor-bearing animals indicated that both CD8(+) and CD4(+) T cells contribute to the regression of contralateral tumors through CTL activation in the periphery and cellular infiltration into tumors. In addition, intratumoral treatment into s.c. tumors of mice bearing metastatic lung tumors with IL13-PE38 showed not only the reduction of treated s.c. tumor but also the reduction of lung metastasis. Thus, IL13-PE38 mediates an antitumor effect not only directly but also indirectly by inducing a host CD8(+) T cell immune response.
Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL13 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9220.269
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-1.4060.356
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2880.846
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1470.394
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL13 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL13. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL13. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL13.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL13. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL13 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL13 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL13
Nameinterleukin 13
Aliases IL-13; ALRH; BHR1; MGC116786; MGC116788; MGC116789; allergic rhinitis; Bronchial hyperresponsiveness-1 (bron ......
Chromosomal Location5q31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL13 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IL13.
ID Name Drug Type Targets #Targets
DB05305Cintredekin BesudotoxBiotechIL131
DB11914LebrikizumabBiotechIL131